Alexander Mansour, MBA
Advertisement
Articles by Alexander Mansour, MBA
The Centers for Medicare and Medicaid Services finalized a ruling that slashes reimbursement rates on drugs that qualify under the 340B program.
Advertisement
Latest Updated Articles
- Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients Lose
Published: January 4th 2018 | Updated:
Opinion: CMS 340B Reimbursement Cuts Cause Big Pharma Profits While Underserved Patients LosePublished: January 3rd 2018 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
Enlicitide Meaningfully Lowers LDL-C at 24 Weeks in Patients At Risk for ASCVD Events
3
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
4
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
5